TargED
targedbiopharmaceuticals.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$65.3M
2 rounds on record
Latest round
$23.2M
Series A · Dec 2025 · 9 mo ago
Team
51-200
employees, estimated range
Backers
3
BioGeneration Ventures, Fund+
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 24, 2025
Raised a round Series A $23.2M · led by BioGeneration Ventures · Pulse 2.0
Feb 21, 2022
Raised a round Venture round $42.1M · pharmaphorum
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Dec 2025 | $23.2M | BioGeneration Ventures lead | Pulse 2.0 |
| Venture round | Feb 2022 | $42.1M | — | pharmaphorum |
Registers and programsofficial lists and records that name the company
| Legal entity | TargED Biopharmaceuticals B.V. | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Fund+ 
Inkef Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Juisci makes scientific publications more accessible, digestible and easier to share within the medical community. Get started now.
星锐医药(Starna Therapeutics) 成立于2021年8月，公司聚焦肝外靶向递送技术，致力于研发以RNA为核心的创新药物，解决未被满足的临床需求。核心团队来自知名药企、高校和研究院所，团队拥有深厚的核酸药物发现、递送技术和制剂开发能力。.
Our therapeutic areas. LifeHealthcare, through our organic growth, and the addition of new organisations is continuing to grow our…
Treat Beyond the Clot.. Real-time data to guide clinical decisions when treating blood clots in the lungs.
Delineate creates models from the totality of available evidence — in any therapeutic area — so development, regulatory, and commercial…
Discover GC Therapeutics, a pioneer in scalable, cutting-edge cell therapies designed to revolutionize treatment across a broad range of…
News
Gwasanaeth iechyd yn debygol o fethu targed rhestrau aros cyn yr etholiad
Mae'n anhebygol y bydd targedau allweddol i ostwng rhestrau aros y gwasanaeth iechyd yn cael eu cyrraedd, yn ôl ymchwil BBC Cymru.
Read more
Report
TargED: €21.5 Million Series A Extension Raised To Advance Targeted Thrombolytic TGD001
TargED Biopharmaceuticals B.V., a clinical-stage biotech company developing targeted treatments for thrombotic diseases, has closed a €21.5 million Series A extension led by BioGeneration Ventures (BGV). Existing investors, including Andera Partners, Fund
Read more
Report
TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreak
TargED United Kingdom United States of America Netherlands
Read more
Report
Cymraeg 2050: 'Isafswm, nid nenfwd, yw targed miliwn o siaradwyr'
Bydd deddf newydd sy'n anelu at gael miliwn o siaradwyr Cymraeg yn cael ei haralleirio i ddatgan yn glir mai isafswm, nid nenfwd, yw'r targed.
Read more
Report
Cymraeg 2050: 'Isafswm, nid nenfwd, yw targed miliwn o siaradwyr'
Bydd deddf newydd sy'n anelu at gael miliwn o siaradwyr Cymraeg yn cael ei haralleirio i ddatgan yn glir mai isafswm, nid nenfwd, yw'r targed.
Read more
Report
TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke (AIS) and TTP
TargED Biopharmaceuticals ("TargED"), a private biotechnology company focused on developing improved treatments for thrombotic diseases, today announces the start of clinical development with the dosing of the first participant with TGD001.
Read more
Report
Targed draws €39M series A to advance anti-thrombosis programs
LONDON - Targed Biopharmaceuticals BV has raised €39 million (US$44.2 million) in a series A financing that will enable it to take its targeted clot busting drug Microlyse into clinical development. The first-in-class product consists of urokinase, a seri
Read more
Report
TargED Bio raises €39m for new clot-busting drug
There's been hardly any change in the use of clot-dissolving (thrombolytic) therapies for conditions like heart attack and stroke for decades, but a small Dutch biotech - TargED Biopharmaceuticals - is hoping to disrupt the market with a new and improved
Read more
Report
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients
Read more
Report
PharmiWeb.com - Thank you
After twenty-five years, PharmiWeb.com is closing. A note of thanks to the pharmaceutical industry community that built it.
Read more
Report
Show more news